证券代码：605266 证券简称：健之佳 公告编号：2025-041 健之佳医药连锁集团股份有限公司关于全资子公司处置资产的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 健之佳医药连锁集团股份有限公司（以下简称"公司"）全资子公司秦皇岛唐人医药连锁有限责任公司 （以下简称"秦皇岛唐人医药"）向自然人赵明女士出售位于秦皇岛市海港区北部工业区的一宗国有出让 工业用地的土地使用权及其地上建筑物的房屋所有权（以下简称"标的资产"），标的资产转让价格预计 为人民币2,400万元整。 ● 本次交易不构成关联交易 ● 本次交易不构成重大资产重组 ● 本次交易在董事会审批权限内，公司于2025年8月18日召开第六届董事会第十一次会议审议通过《关 于全资子公司处置资产的议案》，无需提交股东会审议。 一、交易概述 （一）本次交易的基本情况 1、本次交易概况 根据公司省级区域物流配送效率、成本管控原则及模式，各省级分部建立统一的物流中心负责区域物流 配送。 在河北分部，原由唐山原租赁仓库、秦皇岛自有产权仓库两个 ...

浙江震元最新股价报9.40元，较前一交易日上涨0.02元。盘中最高触及9.49元，最低下探9.38元，成交金 额达1.26亿元。 该公司主营业务为医药商业，涉及医药批发、零售等业务领域。作为区域性医药流通企业，浙江震元在 浙江省内具有一定市场影响力。 根据公司最新公告披露，浙江震元及子公司目前不存在逾期对外担保情况，也未涉及诉讼的对外担保事 项。这一信息披露有助于投资者了解公司财务健康状况。 从资金流向来看，浙江震元当日主力资金净流入742.55万元，近五个交易日累计净流入109.02万元。当 前公司总市值31.41亿元，流通市值26.50亿元。 风险提示：股市有风险，投资需谨慎。 ...

截至2025年8月6日收盘，柳药集团股价报18.33元，较前一交易日下跌0.21元，跌幅1.13%。当日成交量 为102593手，成交金额达1.88亿元。 资金流向方面，8月6日主力资金净流出3280.16万元，近五日主力资金累计净流出272.08万元。 柳药集团是广西地区医药商业龙头企业，主营业务涵盖医药批发、零售和工业三大板块。2024年年报显 示，公司营业收入中批发业务占比78.89%，零售业务占比15.15%，工业业务占比5.49%。 公司8月6日晚间发布公告称，当日通过集中竞价交易方式首次回购股份54.45万股，占总股本0.14%，回 购金额998.28万元，回购价格区间为18.29元至18.36元。根据此前披露的回购方案，公司计划使用1-2亿 元资金进行回购，回购价格上限为25.70元/股，回购期限为12个月。 风险提示：以上内容仅供参考，不构成投资建议。市场有风险，投资需谨慎。 ...

Group 1 - The company Chongqing Pharmaceutical Holdings (SZ 000950) announced on August 5 that as of July 31, 2025, it has not yet implemented the planned share buyback [2] - For the year 2024, the revenue composition of Chongqing Pharmaceutical Holdings is as follows: pharmaceutical wholesale accounts for 95.03%, pharmaceutical retail accounts for 4.59%, and other businesses account for 0.38% [2]

Group 1 - The core viewpoint of the articles indicates that Luyuan Pharmaceutical's revenue has surpassed 20 billion yuan for the first time, reaching 20.471 billion yuan in 2024, with a year-on-year growth of 3.15%, while the net profit attributable to shareholders has declined by 4.92% to 346 million yuan, marking the first negative growth in recent years [2] - From the first quarter of 2024, Luyuan Pharmaceutical's quarterly profits have consistently declined, dropping from a growth of 4.9% to a decline of 14.86% in the first quarter of 2025 [2] - The pharmaceutical wholesale business accounted for 90.8% of total revenue in 2024, but its growth rate was only 1.85%, which negatively impacted overall performance; in contrast, the pharmaceutical retail and industrial businesses maintained double-digit growth rates of 14.46% and 25.16%, respectively, but their revenue contributions were insufficient to reverse the downturn [2] Group 2 - Luyuan Pharmaceutical's business heavily relies on a pure sales model, directly supplying to public hospitals at the secondary level and above, which, while securing quality clients, has led to a continuous rise in accounts receivable [2] - As of the end of 2024, the accounts receivable value was 5.902 billion yuan, accounting for 46.7% of total assets, and by the end of the first quarter of 2025, it further increased to 6.258 billion yuan, approaching 50% [2] - The high accounts receivable directly affects cash flow, with Luyuan Pharmaceutical's net cash flow from operating activities dropping by 55.89% to 577 million yuan in 2024, and a net outflow of 81 million yuan in the first quarter of 2025, although this was a narrowing year-on-year [2] Group 3 - In recent years, Luyuan Pharmaceutical has implemented a "going out of Fujian" strategy through acquisitions, achieving over 96% coverage of secondary hospitals in Sichuan, Jiangxi, and Hainan provinces; however, the effectiveness of regional expansion has varied significantly [3] - In 2024, the revenue contribution from Fujian province was 70.47%, with a growth rate of only 2.19%, nearly stagnant; Sichuan province contributed 16.45% with a year-on-year growth of 10.24%, while Jiangxi province accounted for 9.78% with a decline of 0.81% [3] - Future growth for Luyuan Pharmaceutical will likely depend on seeking development opportunities outside of its home province [3]